Tolerable treatments lacking for higher-risk myelodysplastic syndromes

Health News
Tags :
Health News
Share This :

Tolerable treatments lacking for higher-risk myelodysplastic syndromes

There is a clear, unmet need for tolerable treatments that can produce durable remission among patients with higher-risk myelodysplastic syndromes (HR-MDS), according to a study published online Sept. 7 in Leukemia & Lymphoma.

Shanna Arnold Egloff, Ph.D., from HCA Healthcare in Nashville, Tennessee, and colleagues describe clinical presentation, patient-related factors, prognostic characteristics, treatment patterns, clinical outcomes and resource utilization among 200 patients with HR-MDS within a large U.S. community hospital network.

The researchers found that patients with HR-MDS treated in the community setting were elderly, with a median age of 76 years, and had a high comorbidity burden. First-line therapy was hypomethylating agent (HMA) monotherapy, lenalidomide, and venetoclax (20, 2, and 2 percent, respectively); the remaining patients were treated with supportive care. Within six months of diagnosis, 61 percent of the patients were hospitalized. The overall survival was 11.8 months.

Curative transplantation was rarely used, there was underutilization of HMA-based therapy, and responses were not durable. In addition, most of the patients became transfusion-dependent or transformed to acute myeloid leukemia. Resource utilization was considerable and was highly linked with in-hospital days.

“Our experience confirms that newer approaches to HR-MDS will need to emphasize favorable logistics and coordination of care delivery as well as identify novel therapies with reduced toxicity in an elderly and high comorbidity population to enhance persistence with therapy,” the authors write.

Several authors disclosed ties to HCA Healthcare.

More information:
Shanna Arnold Egloff et al, Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (MDS) in United States community practices, Leukemia & Lymphoma (2023). DOI: 10.1080/10428194.2023.2254429

Copyright © 2023 HealthDay. All rights reserved.

Tolerable treatments lacking for higher-risk myelodysplastic syndromes (2023, October 20)
retrieved 20 October 2023

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Popular News Posts


Our Exclusive Products

Our Store

Our mission is simple, offer quality products that make our customers lives better at a reasonable price, while ensuring a hassle-free shopping experience. This means that before we bring a product to market, we test it to ensure that it meets our high-level quality standards. Our customer service team understand our products and can answer most every product related question quickly and efficiently. We strive everyday to meet and exceed our customers’ expectations of quality and support! Should we ever fail to meet this expectation – contact us and we will make it right!

Our Value: We are proud of our product and accomplishments, but we typically don’t shout it from the rooftop. Instead, we prefer to let our product and customers do the talking. Our core values can be recognized in our product. The qualities we strive for include:

Pragmatism: We design simple, useful solutions for common needs
Quality: From design to final product, we strive for durable solutions that work
Originality: Creativity and innovation are what makes our product unique
Design: Our minimalist and bold design language focuses on functionality and simplicity that is timeless

0 +

Top Rated Products

0 +

Happy Customers